US EditionSCHOTT Pharma Extends CEO Andreas Reisse’s Tenure to 2026 While Appointing Reinhard Mayer as CFO
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
SCHOTT Pharma Extends CEO Andreas Reisse’s Tenure to 2026 While Appointing Reinhard Mayer as CFO
SCHOTT Pharma Extends CEO Andreas Reisse’s Tenure to 2026 While Appointing Reinhard Mayer as CFO (IN BRIEF) SCHOTT Pharma’s Supervisory Board has prolonged CEO Andreas Reisse’s mandate until April 2026, reflecting his pivotal role in driving the company’s emergence as a world-leading manufacturer of pharmaceutical containment and delivery systems. CFO Dr. Almuth Steinkühler will step down on July 31, 2025, having steered the company through its …
CFO change at Schott Pharma: Almuth Steinkühler will resign from the Mainz-based company. Her successor can look back on more than 20 years of CFO experience. Personal changes in Mainz: Chief Financial Officer Almuth Steinkühler will resign from Schott Pharma's position at the end of July of this year after the end of her current contract, the company announced. She will leave Schott Pharma at her own request in order to address a new profession…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
